Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
about
Antioxidant Intake and Antitumor Therapy: Toward Nutritional Recommendations for Optimal ResultsAcute promyelocytic leukemia: where did we start, where are we now, and the futureTargeting of leukemia-initiating cells in acute promyelocytic leukemiaClinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemiaArsenic as Traditional Chinese Medicine Provides New Hope for Overcoming High Treatment Costs of Acute Promyelocytic Leukemia.Realgar quantum dots induce apoptosis and necrosis in HepG2 cells through endoplasmic reticulum stressMutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic TrioxideEffects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.Fabrication of water-soluble polymer-encapsulated As4S4 to increase oral bioavailability and chemotherapeutic efficacy in AML mice.The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia.Induction treatments for acute promyelocytic leukemia: a network meta-analysis.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Contemporary treatment of APLWhat is the standard regimen for patients with acute promyelocytic leukemia?Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Therapeutic and analytical applications of arsenic binding to proteins.Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.Recent advances in acute promyelocytic leukaemia.Fighting against hematological malignancy in China: from unique system to global impact.Current standard treatment of adult acute promyelocytic leukaemia.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL).A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Tetra-arsenic tetra-sulfide induces cell cycle arrest and apoptosis in retinoic acid-resistant acute promyelocytic leukemia cells.Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database.Effects of Arsenic Trioxide on Minor Progressive High-Grade Osteosarcoma of the Extremities Metastatic to the Lung: Results of 39 Patients Treated in a Single Institution.Inhibition of STAT3/VEGF/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells.Toward evidence-based Chinese medicine: Status quo, opportunities and challenges.Acute WT1-positive promyelocytic leukemia with hypogranular variant morphology, bcr-3 isoform of PML-RARα and Flt3-ITD mutation: a rare case report.Anticancer efficacies of arsenic disulfide through apoptosis induction, cell cycle arrest, and pro-survival signal inhibition in human breast cancer cells.Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations.Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.Absorption Characteristics of Combination Medication of Realgar and : Transport across MDCK-MDR1 Cells and Pharmacokinetics in Mice after Oral Administration
P2860
Q26774897-F4A87427-59D8-4FF9-8F8F-D59C9958DEF1Q26830385-E53623DE-A575-4B4E-9358-D9466867C243Q28083807-7D764989-D0A7-4321-AEE4-19159A81391EQ33746130-CCE540ED-9CC5-47E3-BA47-13E3ABA61889Q33859679-A76A35D4-C8DC-414D-9824-8887BAC25E8DQ35787483-80613543-A11C-4FD8-9F81-47B223BA5271Q35949253-F2DD86E7-8715-483D-A8C6-65F235C7DDA3Q36803750-D0C2804B-7F08-4F5E-AD75-38EA788111E9Q36941941-0F395C9E-A502-4355-A9DD-469E326555EAQ37072906-E1304DE9-DF08-4531-A537-EA94875E8919Q37296118-D41E8187-6C6A-4E1A-88C4-0FA9F8821DDBQ37565126-F176AAAE-94E6-4C3C-B95D-19B4F84D83DDQ37574635-ED4E3ABA-5853-4011-BD68-94C7A383A367Q37687750-981DA0CE-2EF6-4BDA-B82A-38C2E29DA66EQ37712353-3655255C-B5F0-4C99-AFFF-2BE3A55102C4Q38197074-5458C7BC-4D04-4A61-89CC-1DCF99AE5000Q38204310-602749B1-290B-426D-82B2-A35302DBEA8EQ38221006-E9AD7129-615F-40F8-931F-369B19D72F47Q38232465-934E6712-93DA-481B-ABE0-B2F78FFE4ECDQ38263881-FE42E76D-B8AE-4957-96DC-BBD2C83AAD8DQ38522309-73442D8F-1D10-445E-817A-79CD20EF24AAQ38556985-8866F3BA-3411-43C7-9B6B-D203A9079DBAQ38632968-A6B006F0-0340-4083-9490-DAAC43948820Q38674575-CF9F4C69-9F22-4F81-93E4-48D1637E17A9Q38798789-21B55E43-0717-4939-A3F4-A99E2B440437Q41141216-B6A899EC-B0D3-406E-90AA-743785268C5DQ41385777-9E8C32A0-F7F6-488B-AC95-EC444B1B365AQ41556358-7C65BF64-1AD9-41AE-BC1E-8B910D06B436Q41662169-4A20FDF3-091B-4F07-82C0-91084EB87AB8Q42364914-66F87CBD-95A1-4EC2-8DE8-14968C5F3EB5Q47118750-A7FA526E-7503-4A05-93CD-50D2B6ED83FFQ47655060-0820A096-B657-45A5-A364-DD819960AA33Q51167811-217B21CB-F023-4B95-85B7-F7C895611448Q52720134-E34D6A3F-44AC-4C2E-827D-857650474BCBQ53728637-B1E76768-B12E-4FAA-8DE0-EA978E012719Q53751817-6AB10C7F-5F89-4228-A449-DAF2EFCA8BE0Q58761147-A422D37F-4A9D-44E0-B02F-F3AB27D30B81
P2860
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Oral tetra-arsenic tetra-sulfi ...... r randomized controlled trial.
@en
type
label
Oral tetra-arsenic tetra-sulfi ...... r randomized controlled trial.
@en
prefLabel
Oral tetra-arsenic tetra-sulfi ...... r randomized controlled trial.
@en
P2093
P356
P1476
Oral tetra-arsenic tetra-sulfi ...... er randomized controlled trial
@en
P2093
Hong-Hu Zhu
Jian-Xiang Wang
Jian-Yong Li
Sai-Juan Chen
P304
P356
10.1200/JCO.2013.48.8312
P407
P577
2013-10-14T00:00:00Z